282 related articles for article (PubMed ID: 19070505)
1. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis.
Tubiana-Hulin M; Spielmann M; Roux C; Campone M; Zelek L; Gligorov J; Samson J; Lesclous P; Laredo JD; Namer M
Crit Rev Oncol Hematol; 2009 Jul; 71(1):12-21. PubMed ID: 19070505
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management.
Ruggiero SL; Mehrotra B
Annu Rev Med; 2009; 60():85-96. PubMed ID: 18928335
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
Landesberg R; Wilson T; Grbic JT
Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
[TBL] [Abstract][Full Text] [Related]
5. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
Diel IJ; Fogelman I; Al-Nawas B; Hoffmeister B; Migliorati C; Gligorov J; Väänänen K; Pylkkänen L; Pecherstorfer M; Aapro MS
Crit Rev Oncol Hematol; 2007 Dec; 64(3):198-207. PubMed ID: 17855108
[TBL] [Abstract][Full Text] [Related]
7. [Bisphosphonates and osteonecrosis of the jaws].
Urade M
Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
9. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of intravenous bisphosphonates.
Mehrotra B
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S24-7. PubMed ID: 18068487
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate-induced necrosis of the jaws: a reconstructive nightmare.
Gevorgyan A; Enepekides DJ
Curr Opin Otolaryngol Head Neck Surg; 2008 Aug; 16(4):325-30. PubMed ID: 18626250
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-associated osteonecrosis of the jaw. A proposal for conservative treatment.
Pérez SB; Barrero MV; Hernández MS; Knezevic M; Navarro JM; Millares JR
Med Oral Patol Oral Cir Bucal; 2008 Dec; 13(12):E770-3. PubMed ID: 19047964
[TBL] [Abstract][Full Text] [Related]
14. Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient.
Koka S; Clarke BL; Amin S; Gertz M; Ruggiero SL
Int J Prosthodont; 2007; 20(2):115-22. PubMed ID: 17455429
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
Fehm T; Felsenberg D; Krimmel M; Solomayer E; Wallwiener D; Hadjii P
Breast; 2009 Aug; 18(4):213-7. PubMed ID: 19651512
[TBL] [Abstract][Full Text] [Related]
17. Association between osteonecrosis of the jaws and chronic high-dosage intravenous bisphosphonates therapy.
Graziani F; Cei S; La Ferla F; Cerri E; Itro A; Gabriele M
J Craniofac Surg; 2006 Sep; 17(5):876-9. PubMed ID: 17003614
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and osteonecrosis of the jaw.
Sambrook P; Olver I; Goss A
Aust Fam Physician; 2006 Oct; 35(10):801-3. PubMed ID: 17019456
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates.
Bagán J; Blade J; Cozar JM; Constela M; García Sanz R; Gómez Veiga F; Lahuerta JJ; Lluch A; Massuti B; Morote J; San Miguel JF; Solsona E
Med Oral Patol Oral Cir Bucal; 2007 Aug; 12(4):E336-40. PubMed ID: 17664922
[No Abstract] [Full Text] [Related]
20. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review.
Silverman SL; Landesberg R
Am J Med; 2009 Feb; 122(2 Suppl):S33-45. PubMed ID: 19187811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
